Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience.

被引：1
|
作者：
Advani, R
Maeda, L
Hoppe, RT
Breslin, S
Rosenberg, SA
Baer, D
Mason, J
Horning, SJ
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] No Calif Kaiser Permanente, Oakland, CA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1932.1932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1932
引用
收藏
页码：548A / 548A
页数：1
相关论文
共 50 条
  • [31] Elderly patients with early-unfavorable stage Hodgkin's disease have a poorer outcome when treated with combined modality treatment and extended field radiotherapy
    Eich, HT
    Müller, RP
    Engert, A
    Klimm, B
    Schlen, S
    Dühmke, E
    Skripnitchenko, R
    Diehl, V
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 : 113 - 113
  • [32] Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492
    Horning, SJ
    Wiliams, J
    Bartlett, NL
    Bennett, JM
    Hoppe, RT
    Neuberg, D
    Cassileth, P
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) : 972 - 980
  • [33] Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles ABVD in early stage Hodgkin's disease:: interim results of the German Hodgkin's Lymphoma Study Group (GHSG) trial hd10
    Müller, RP
    Eich, HT
    Wolf, J
    Pfistner, B
    Engert, A
    Diehl, V
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S205 - S205
  • [34] Involved field(IF) vs. extended field (EF) radiotherapy (RT) for patients in early unfavorable stages of Hodgkin's lymphoma (HL): 10-year update of the HD8 trial of the German Hodgkin Study Group (GHSG)
    Kriz, J.
    Sasse, S.
    Klimm, B.
    Goergen, H.
    Mueller, R. -P
    Diehl, V
    Borchmann, P.
    Engert, A.
    Eich, H. -T
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 30 - 30
  • [35] Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: Cure balanced against complications
    Koontz, BF
    Kirkpatrick, JP
    Clough, RW
    Prosnitz, RG
    Gockerman, JP
    Moore, JO
    Prosnitz, LR
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) : 605 - 611
  • [36] Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD
    Enrici, RM
    Anselmo, AP
    Donato, V
    Osti, MF
    Santoro, M
    Tombolini, V
    Mandelli, F
    HAEMATOLOGICA, 1999, 84 (10) : 917 - 923
  • [37] ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
    Gobbi, PG
    Levis, A
    Chisesi, T
    Broglia, C
    Vitolo, U
    Stelitano, C
    Pavone, V
    Cavanna, L
    Santini, G
    Merli, F
    Liberati, M
    Baldini, L
    Deliliers, GL
    Angelucci, E
    Bordonaro, R
    Federico, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9198 - 9207
  • [38] Intermediate stage Hodgkin's disease:: Preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy
    Anselmo, AP
    Cavalieri, E
    Osti, FM
    Cantonetti, M
    De Sanctis, V
    Alfo, M
    Amadori, S
    Enrici, RM
    ANTICANCER RESEARCH, 2004, 24 (06) : 4045 - 4050
  • [39] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group
    Engert, A
    Schiller, P
    Josting, A
    Herrmann, R
    Koch, P
    Sieber, M
    Boissevain, F
    de Wit, M
    Mezger, J
    Dühmke, E
    Willich, N
    Müller, RP
    Schmidt, BF
    Renner, H
    Müller-Hermelink, HK
    Pfistner, B
    Wolf, J
    Hasenclever, D
    Löffler, M
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3601 - 3608
  • [40] RELATIVE RISK (RR) OF SECONDARY MALIGNANCIES (SM) IN PATIENTS (PT) TREATED BY RADIOTHERAPY (RT) OR RT PLUS CHEMOTHERAPY (CT) IN COMPARISON WITH PATIENTS TREATED BY CT ALONE FOR HODGKIN'S DISEASE: EXPERIENCE FROM A SINGLE INSTITUTION
    Petrakova, K.
    Vyskocil, J.
    Palacova, M.
    Komolikova, L.
    Vyzula, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 232 - 233
12345